← Research & Industry News
External source
Sensible Bio secures $47M Series A for mRNA therapy manufacturing platform
Sensible Biotechnologies is looking to mark its territory in the increasingly hot space of mRNA therapeutics, raising $47 million in a Series A round to develop its manufacturing approach. “Current mRNA technology is fine for ...
- Published by
- Endpoints News
- Evidence type
- Laboratory
Sensible Biotechnologies is looking to mark its territory in the increasingly hot space of mRNA therapeutics, raising $47 million in a Series A round to develop its manufacturing approach. “Current mRNA technology is fine for ...
This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at Endpoints News.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.